The bradykinin B1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbits.

Can J Physiol Pharmacol

Department of Pharmacology, Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, UK.

Published: April 2002

There are two bradykinin receptor subtypes, designated B1 and B2. Whilst both have been implicated in nociception, it is believed that there is a low level of constitutive expression of B1 receptors and that their expression is induced by inflammation or tissue damage. The present study investigated the role of B1 receptors in spinal nociceptive processing using an in vivo electrophysiological assay in decerebrate, spinalized rabbits, a species that shares close B1 receptor homology with the human receptor. Inflammation was induced in the paw by an injection of complete Freund's adjuvant at least 1 h before recording single motor unit activity of the semitendinous/biceps femoris muscle in response to a noxious pinch of the foot. Control animals received an intraplantar injection of saline. The peptide B1 receptor antagonist B9858 was administered i.v. and caused dose-dependent and complete inhibition of the nociceptive spinal reflex (ID50 = 1 mg x kg(-1)). In control animals without paw inflammation, B9858 had no effect. These findings are consistent with other evidence that peptide B1 receptor antagonists inhibit spinal nociceptive reflexes only after induction of B1 receptors by inflammation and support the potential therapeutic utility of B1 receptor antagonists as analgesic and anti-inflammatory drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1139/y02-049DOI Listing

Publication Analysis

Top Keywords

bradykinin receptor
8
receptor antagonist
8
antagonist b9858
8
nociceptive spinal
8
spinal reflex
8
spinal nociceptive
8
control animals
8
peptide receptor
8
receptor antagonists
8
receptor
6

Similar Publications

Neurochemical mechanism of muscular pain: Insight from the study on delayed onset muscle soreness.

J Physiol Sci

January 2025

Department of Physical Therapy, Faculty of Rehabilitation, Niigata University of Health and Welfare, 950-3198, Niigata, Japan; Institute for Human Movement and Medical Sciences (IHMMS), Niigata University of Health and Welfare, 950-3198, Niigata, Japan.

We reviewed fundamental studies on muscular pain, encompassing the characteristics of primary afferent fibers and neurons, spinal and thalamic projections, several muscular pain models, and possible neurochemical mechanisms of muscle pain. Most parts of this review were based on data obtained from animal experiments, and some researches on humans were also introduced. We focused on delayed-onset muscle soreness (DOMS) induced by lengthening contractions (LC), suitable for studying myofascial pain syndromes.

View Article and Find Full Text PDF

Inhibition of mPFC norepinephrine improved chronic post-thoracotomy pain in adult rats.

Ann Med

December 2025

Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.

Background: Chronic post-thoracotomy pain (CPTP) is characterized by high incidence, long duration, and severity of pain. Medial prefrontal cortex (mPFC) is a brain region closely associated with chronic pain, and norepinephrine is involved in pain regulation. But the role of mPFC norepinephrine in CPTP and its possible mechanism is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • SARS-CoV-2 can infect liver cells (hepatocytes), leading to elevated liver enzymes and more severe disease in those with pre-existing liver conditions.
  • The study shows that the virus replicates and spreads in hepatocytes, with infection being dependent on two specific proteins, ACE2 and TMPRSS2, which are found on the liver cells.
  • Infection causes rapid liver cell death, with the Omicron variant causing quicker but less extensive damage compared to other strains, as seen in both human liver cells and infected mice.
View Article and Find Full Text PDF

Novel strategies are needed for the treatment of acute ischemic stroke when revascularization therapies are not clinically appropriate or are unsuccessful. rKLK1 (recombinant human tissue kallikrein-1), a bradykinin-producing enzyme, offers a promising potential solution. In animal studies of acute stroke, there is a marked 36-fold increase in bradykinin B2 receptor on brain endothelial cells of the ischemic region.

View Article and Find Full Text PDF

Over the past 2 decades, guidelines for the on-demand treatment of hereditary angioedema attacks have undergone significant evolution. Early treatment guidelines, such as the Canadian 2003 International Consensus Algorithm, often gated on-demand treatment by attack location and/or severity. Pivotal trials for on-demand injectable treatments (plasma-derived C1 esterase inhibitor, icatibant, ecallantide [United States only], and recombinant human C1 esterase inhibitor), which were approved in the United States and the European Union between 2008 and 2014, were designed accordingly.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!